Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Baclofen
Form:
24 of 24 products shown
12 general benefit · 12 not a benefit
Apo-Baclofen · DIN 02139332 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Baclofen · DIN 02139332
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1994-12-31 · brand APO-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Apotex inc · schedule Prescription
DIN 02139332: Apo-Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02139332
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17246Interchangeable products
Baclofen · DIN 02287021 · $0.1595
Baclofen · DIN 02544660 · $0.1595
Jamp Baclofen · DIN 02544482 · $0.1595
Lioresal · DIN 00455881 · $0.1595
Mylan-Baclofen · DIN 02088398 · $0.1595
PMS-Baclofen · DIN 02063735 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: resolved shortage (ended August 29, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02139332
Shortage record checked October 6, 2026
Baclofen · DIN 02287021 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Baclofen · DIN 02287021
Manufacturer: Sanis Health Inc.; listing date 2011-09-15
Health Canada: Marketed since 2010-02-25 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Sanis health inc · schedule Prescription
DIN 02287021: Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287021
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77246Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595
Baclofen · DIN 02544660 · $0.1595
Jamp Baclofen · DIN 02544482 · $0.1595
Lioresal · DIN 00455881 · $0.1595
Mylan-Baclofen · DIN 02088398 · $0.1595
PMS-Baclofen · DIN 02063735 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: resolved shortage (ended January 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287021
Shortage record checked October 6, 2026
Baclofen · DIN 02544660 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Baclofen · DIN 02544660
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-10-31
Health Canada: Marketed since 2024-05-31 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
DIN 02544660: Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544660
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103323Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595
Baclofen · DIN 02287021 · $0.1595
Jamp Baclofen · DIN 02544482 · $0.1595
Lioresal · DIN 00455881 · $0.1595
Mylan-Baclofen · DIN 02088398 · $0.1595
PMS-Baclofen · DIN 02063735 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544660
Shortage record checked October 6, 2026
Jamp Baclofen · DIN 02544482 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Baclofen · DIN 02544482
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-09-12 · brand JAMP BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp Baclofen: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1595). What the ministry pays, not the patient.
Ministry pays: $0.1595 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02544482: Jamp Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544482
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103303Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595
Baclofen · DIN 02287021 · $0.1595
Baclofen · DIN 02544660 · $0.1595
Lioresal · DIN 00455881 · $0.1595
Mylan-Baclofen · DIN 02088398 · $0.1595
PMS-Baclofen · DIN 02063735 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544482
Shortage record checked October 6, 2026
Mylan-Baclofen · DIN 02088398 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Baclofen · DIN 02088398
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Health Canada: Marketed since 2010-01-20 · brand MYLAN-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Baclofen: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1595). What the ministry pays, not the patient.
Ministry pays: $0.1595 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02088398: Mylan-Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id MYL
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02088398
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16534Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595
Baclofen · DIN 02287021 · $0.1595
Baclofen · DIN 02544660 · $0.1595
Jamp Baclofen · DIN 02544482 · $0.1595
Lioresal · DIN 00455881 · $0.1595
PMS-Baclofen · DIN 02063735 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: resolved shortage (ended August 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02088398
Shortage record checked October 6, 2026
PMS-Baclofen · DIN 02063735 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Baclofen · DIN 02063735
Manufacturer: Pharmascience Inc.; listing date 1996-10-01
Health Canada: Marketed since 1994-12-31 · brand PMS-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Pharmascience inc · schedule Prescription
DIN 02063735: PMS-Baclofen
Raw flags: sec3=Y
Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1595; ministry $0.1595
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02063735
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15547Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595
Baclofen · DIN 02287021 · $0.1595
Baclofen · DIN 02544660 · $0.1595
Jamp Baclofen · DIN 02544482 · $0.1595
Lioresal · DIN 00455881 · $0.1595
Mylan-Baclofen · DIN 02088398 · $0.1595
Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: resolved shortage (ended January 24, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02063735
Shortage record checked October 6, 2026
Apo-Baclofen · DIN 02139391 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Baclofen · DIN 02139391
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1994-12-31 · brand APO-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Apotex inc · schedule Prescription
DIN 02139391: Apo-Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02139391
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17247Interchangeable products
Baclofen · DIN 02287048 · $0.3104
Baclofen · DIN 02544679 · $0.3104
Jamp Baclofen · DIN 02544490 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
Mylan-Baclofen · DIN 02088401 · $0.3104
PMS-Baclofen · DIN 02063743 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: resolved shortage (ended May 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02139391
Shortage record checked October 6, 2026
Baclofen · DIN 02287048 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Baclofen · DIN 02287048
Manufacturer: Sanis Health Inc.; listing date 2011-09-15
Health Canada: Marketed since 2010-02-25 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Sanis health inc · schedule Prescription
DIN 02287048: Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287048
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77247Interchangeable products
Apo-Baclofen · DIN 02139391 · $0.3104
Baclofen · DIN 02544679 · $0.3104
Jamp Baclofen · DIN 02544490 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
Mylan-Baclofen · DIN 02088401 · $0.3104
PMS-Baclofen · DIN 02063743 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: resolved shortage (ended September 22, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287048
Shortage record checked October 6, 2026
Baclofen · DIN 02544679 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Baclofen · DIN 02544679
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-10-31
Health Canada: Marketed since 2024-05-31 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
DIN 02544679: Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544679
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103324Interchangeable products
Apo-Baclofen · DIN 02139391 · $0.3104
Baclofen · DIN 02287048 · $0.3104
Jamp Baclofen · DIN 02544490 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
Mylan-Baclofen · DIN 02088401 · $0.3104
PMS-Baclofen · DIN 02063743 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544679
Shortage record checked October 6, 2026
Jamp Baclofen · DIN 02544490 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Baclofen · DIN 02544490
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-09-12 · brand JAMP BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Jamp pharma corporation · schedule Prescription
Jamp Baclofen: Formulary list price $0.31 per unit (the source does not state the unit; exact figure $0.3104). What the ministry pays, not the patient.
Ministry pays: $0.3104 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02544490: Jamp Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544490
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103304Interchangeable products
Apo-Baclofen · DIN 02139391 · $0.3104
Baclofen · DIN 02287048 · $0.3104
Baclofen · DIN 02544679 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
Mylan-Baclofen · DIN 02088401 · $0.3104
PMS-Baclofen · DIN 02063743 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544490
Shortage record checked October 6, 2026
Mylan-Baclofen · DIN 02088401 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Baclofen · DIN 02088401
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Health Canada: Marketed since 2010-03-24 · brand MYLAN-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Baclofen: Formulary list price $0.31 per unit (the source does not state the unit; exact figure $0.3104). What the ministry pays, not the patient.
Ministry pays: $0.3104 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02088401: Mylan-Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id MYL
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02088401
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16532Interchangeable products
Apo-Baclofen · DIN 02139391 · $0.3104
Baclofen · DIN 02287048 · $0.3104
Baclofen · DIN 02544679 · $0.3104
Jamp Baclofen · DIN 02544490 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
PMS-Baclofen · DIN 02063743 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: resolved shortage (ended October 23, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02088401
Shortage record checked October 6, 2026
PMS-Baclofen · DIN 02063743 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Baclofen · DIN 02063743
Manufacturer: Pharmascience Inc.; listing date 1996-10-01
Health Canada: Marketed since 1994-12-31 · brand PMS-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Pharmascience inc · schedule Prescription
DIN 02063743: PMS-Baclofen
Raw flags: sec3=Y
Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3104; ministry $0.3104
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02063743
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15548Interchangeable products
Apo-Baclofen · DIN 02139391 · $0.3104
Baclofen · DIN 02287048 · $0.3104
Baclofen · DIN 02544679 · $0.3104
Jamp Baclofen · DIN 02544490 · $0.3104
Lioresal DS · DIN 00636576 · $0.3104
Mylan-Baclofen · DIN 02088401 · $0.3104
Ratio-Baclofen · DIN 02236508 · $0.3104
Shortage status: resolved shortage (ended February 16, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02063743
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Injection · DIN 02413620
Manufacturer: Sterimax Inc.; listing date 2015-08-26
Health Canada: Marketed since 2018-01-12 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.05 MG/1ML · company Sterimax inc · schedule Prescription
Baclofen Injection: Formulary list price $11.25 per unit (the source does not state the unit; exact figure $11.2500). What the ministry pays, not the patient.
Ministry pays: $11.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413620).
DIN 02413620: Baclofen Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000024; group id 240; item number 0428; lccId None; manufacturer id STE
Source form: Inj Sol-1mL Pk (Preservative-Free); strength: 0.05mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $11.2500; ministry $11.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413620
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89827Interchangeable products
Baclofen Injection · DIN 02457059 · $11.2500
Lioresal Intrathecal · DIN 02131048 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413620
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Intrathecal · DIN 02413639
Manufacturer: Sterimax Inc.; listing date 2015-08-26
Health Canada: Marketed since 2018-01-11 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 10 MG/20ML · company Sterimax inc · schedule Prescription
Baclofen Intrathecal: Formulary list price $177.25 per unit (the source does not state the unit; exact figure $177.2500). What the ministry pays, not the patient.
Ministry pays: $177.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413639).
DIN 02413639: Baclofen Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id STE
Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $177.2500; ministry $177.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413639
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89828Interchangeable products
Baclofen Injection · DIN 02457067 · $177.2500
Baclofen Intrathecal · DIN 02485508 · $177.2500
Lioresal Intrathecal · DIN 02131056 · not recorded
Shortage status: resolved shortage (ended September 19, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413639
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Intrathecal · DIN 02485508
Manufacturer: Avir Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2021-07-20 · brand BACLOFEN INTRATHECAL · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.5 MG/ML · company Avir pharma inc. · schedule Prescription
Baclofen Intrathecal: Formulary list price $177.25 per unit (the source does not state the unit; exact figure $177.2500). What the ministry pays, not the patient.
Ministry pays: $177.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02485508).
DIN 02485508: Baclofen Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id AVP
Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $177.2500; ministry $177.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485508
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97574Interchangeable products
Baclofen Injection · DIN 02457067 · $177.2500
Baclofen Intrathecal · DIN 02413639 · $177.2500
Lioresal Intrathecal · DIN 02131056 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485508
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Injection · DIN 02457075
Manufacturer: Teligent OU; listing date 2019-02-28
Health Canada: Marketed since 2023-05-26 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Hikma canada limited · schedule Prescription
Baclofen Injection: Formulary list price $35.45 per unit (the source does not state the unit; exact figure $35.4500). What the ministry pays, not the patient.
Ministry pays: $35.4500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02457075).
DIN 02457075: Baclofen Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id TEL
Source form: Inj Sol (Preservative-Free); strength: 2mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $35.4500; ministry $35.4500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457075
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94416Interchangeable products
Baclofen Injection USP · DIN 02553341 · $35.4500
Baclofen Intrathecal · DIN 02413647 · $35.4500
Baclofen Intrathecal · DIN 02485516 · $35.4500
Lioresal Intrathecal · DIN 02131064 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457075
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Injection USP · DIN 02553341
Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31
Health Canada: Marketed since 2025-11-10 · brand BACLOFEN INJECTION USP · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Jamp pharma corporation · schedule Prescription
Baclofen Injection USP: Formulary list price $35.45 per unit (the source does not state the unit; exact figure $35.4500). What the ministry pays, not the patient.
Ministry pays: $35.4500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02553341).
DIN 02553341: Baclofen Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id JPC
Source form: Inj Sol (Preservative-Free); strength: 2mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $35.4500; ministry $35.4500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02553341
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104229Interchangeable products
Baclofen Injection · DIN 02457075 · $35.4500
Baclofen Intrathecal · DIN 02413647 · $35.4500
Baclofen Intrathecal · DIN 02485516 · $35.4500
Lioresal Intrathecal · DIN 02131064 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553341
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Intrathecal · DIN 02413647
Manufacturer: Sterimax Inc.; listing date 2015-08-26
Health Canada: Marketed since 2018-01-11 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 10 MG/5ML · company Sterimax inc · schedule Prescription
Baclofen Intrathecal: Formulary list price $35.45 per unit (the source does not state the unit; exact figure $35.4500). What the ministry pays, not the patient.
Ministry pays: $35.4500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413647).
DIN 02413647: Baclofen Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id STE
Source form: Inj Sol (Preservative-Free); strength: 2mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $35.4500; ministry $35.4500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413647
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89829Interchangeable products
Baclofen Injection · DIN 02457075 · $35.4500
Baclofen Injection USP · DIN 02553341 · $35.4500
Baclofen Intrathecal · DIN 02485516 · $35.4500
Lioresal Intrathecal · DIN 02131064 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413647
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Intrathecal · DIN 02485516
Manufacturer: Avir Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2021-07-20 · brand BACLOFEN INTRATHECAL · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Avir pharma inc. · schedule Prescription
Baclofen Intrathecal: Formulary list price $35.45 per unit (the source does not state the unit; exact figure $35.4500). What the ministry pays, not the patient.
Ministry pays: $35.4500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02485516).
DIN 02485516: Baclofen Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id AVP
Source form: Inj Sol (Preservative-Free); strength: 2mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $35.4500; ministry $35.4500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485516
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97575Interchangeable products
Baclofen Injection · DIN 02457075 · $35.4500
Baclofen Injection USP · DIN 02553341 · $35.4500
Baclofen Intrathecal · DIN 02413647 · $35.4500
Lioresal Intrathecal · DIN 02131064 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485516
Off-Formulary Interchangeable, not an ODB benefitDormant since June 19, 2026 · checked October 5, 2026 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Injection · DIN 02457059
Manufacturer: Teligent OU; listing date 2019-02-28
Health Canada: Dormant since 2026-06-19 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.05 MG/ML · company Hikma canada limited · schedule Prescription
Baclofen Injection: Formulary list price $11.25 per unit (the source does not state the unit; exact figure $11.2500). What the ministry pays, not the patient.
Ministry pays: $11.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02457059).
DIN 02457059: Baclofen Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000024; group id 240; item number 0428; lccId None; manufacturer id TEL
Source form: Inj Sol-1mL Pk (Preservative-Free); strength: 0.05mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $11.2500; ministry $11.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457059
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94414Interchangeable products
Baclofen Injection · DIN 02413620 · $11.2500
Lioresal Intrathecal · DIN 02131048 · not recorded
Shortage status: active shortage (reported May 26, 2023, last updated May 27, 2023) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457059
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since June 19, 2026 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefitDormant since June 19, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Baclofen Injection · DIN 02457067
Manufacturer: Teligent OU; listing date 2019-02-28
Health Canada: Dormant since 2026-06-19 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.5 MG/ML · company Hikma canada limited · schedule Prescription
Baclofen Injection: Formulary list price $177.25 per unit (the source does not state the unit; exact figure $177.2500). What the ministry pays, not the patient.
Ministry pays: $177.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02457067).
DIN 02457067: Baclofen Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id TEL
Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $177.2500; ministry $177.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457067
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94415Interchangeable products
Baclofen Intrathecal · DIN 02413639 · $177.2500
Baclofen Intrathecal · DIN 02485508 · $177.2500
Lioresal Intrathecal · DIN 02131056 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457067
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since June 19, 2026 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-02-07 — choose a marketed DIN from the same-category list.Discontinued February 7, 2025 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-02-07 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2025-02-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Lioresal Intrathecal · DIN 02131048
Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-08-26
Health Canada: Cancelled post market since 2025-02-07 · brand LIORESAL INTRATHECAL 0.05MG/ML · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.05 MG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Lioresal Intrathecal: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02131048).
DIN 02131048: Lioresal Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000024; group id 240; item number 0428; lccId None; manufacturer id NOV
Source form: Inj Sol-1mL Pk (Preservative-Free); strength: 0.05mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02131048
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17277Interchangeable products
Baclofen Injection · DIN 02413620 · $11.2500
Baclofen Injection · DIN 02457059 · $11.2500
Shortage status: discontinued (September 1, 2023, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02131048
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 7, 2025 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-28 — choose a marketed DIN from the same-category list.Discontinued August 28, 2023 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-28 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2023-08-28 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Lioresal Intrathecal · DIN 02131056
Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-08-26
Health Canada: Cancelled post market since 2023-08-28 · brand LIORESAL INTRATHECAL 0.5MG/ML · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.5 MG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Lioresal Intrathecal: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02131056).
DIN 02131056: Lioresal Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id NOV
Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02131056
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17954Interchangeable products
Baclofen Injection · DIN 02457067 · $177.2500
Baclofen Intrathecal · DIN 02413639 · $177.2500
Baclofen Intrathecal · DIN 02485508 · $177.2500
Shortage status: discontinued (September 1, 2023, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02131056
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 28, 2023 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-10-06 — choose a marketed DIN from the same-category list.Discontinued October 6, 2023 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-10-06 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2023-10-06 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Lioresal Intrathecal · DIN 02131064
Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-08-26
Health Canada: Cancelled post market since 2023-10-06 · brand LIORESAL INTRATHECAL 2MG/ML · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Lioresal Intrathecal: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02131064).
DIN 02131064: Lioresal Intrathecal
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id NOV
Source form: Inj Sol (Preservative-Free); strength: 2mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02131064
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17276Interchangeable products
Baclofen Injection · DIN 02457075 · $35.4500
Baclofen Injection USP · DIN 02553341 · $35.4500
Baclofen Intrathecal · DIN 02413647 · $35.4500
Baclofen Intrathecal · DIN 02485516 · $35.4500
Shortage status: discontinued (September 1, 2023, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02131064
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 6, 2023 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (M03B, M03BX): coverage varies; not interchangeable
Cyclobenzaprine (Flexeril): not a benefit
Tizanidine (Zanaflex): not a benefit
Orphenadrine (Norflex): not a benefit
Other drugs in the same formulary class (12:20 Skeletal Muscle Relaxants) and how they are covered
Matched class: 12:20 Skeletal Muscle Relaxants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DANTROLENE SODIUM
12:20 Skeletal Muscle Relaxants
· 1 products · General benefit · strengths: 25mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:20
INDICATIONS AND CLINICAL USE
pms-BACLOFEN (baclofen) is useful for the alleviation of signs and symptoms of spasticity
resulting from multiple sclerosis.
pms-BACLOFEN may also be of some value in patients with spinal cord injuries and other
spinal cord diseases.
https://pdf.hres.ca/dpd_pm/00059369.PDF
PM date: December 11, 2020
Source product: PMS-BACLOFEN; DIN 02063735; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Baclofen Intrathecal · DIN 02485508
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485508
Baclofen Intrathecal · DIN 02485516
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485516
Baclofen Injection · DIN 02457059
Shortage status: active shortage (reported 2023-05-26, last updated 2023-05-27) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457059
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Baclofen Injection, Baclofen Intrathecal, Baclofen Injection USP, Lioresal Intrathecal: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.